3O50

Crystal structure of benzamide 9 bound to AuroraA


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.351 
  • R-Value Work: 0.285 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.

Cee, V.J.Schenkel, L.B.Hodous, B.L.Deak, H.L.Nguyen, H.N.Olivieri, P.R.Romero, K.Bak, A.Be, X.Bellon, S.Bush, T.L.Cheng, A.C.Chung, G.Coats, S.Eden, P.M.Hanestad, K.Gallant, P.L.Gu, Y.Huang, X.Kendall, R.L.Lin, M.H.Morrison, M.J.Patel, V.F.Radinsky, R.Rose, P.E.Ross, S.Sun, J.R.Tang, J.Zhao, H.Payton, M.Geuns-Meyer, S.D.

(2010) J.Med.Chem. 53: 6368-6377

  • DOI: 10.1021/jm100394y
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The discovery of aurora kinases as essential regulators of cell division has led to intense interest in identifying small molecule aurora kinase inhibitors for the potential treatment of cancer. A high-throughput screening effort identified pyridinyl ...

    The discovery of aurora kinases as essential regulators of cell division has led to intense interest in identifying small molecule aurora kinase inhibitors for the potential treatment of cancer. A high-throughput screening effort identified pyridinyl-pyrimidine 6a as a moderately potent dual inhibitor of aurora kinases -A and -B. Optimization of this hit resulted in an anthranilamide lead (6j) that possessed improved enzyme and cellular activity and exhibited a high level of kinase selectivity. However, this anthranilamide and subsequent analogues suffered from a lack of oral bioavailability. Converting the internally hydrogen-bonded six-membered pseudo-ring of the anthranilamide to a phthalazine (8a-b) led to a dramatic improvement in oral bioavailability (38-61%F) while maintaining the potency and selectivity characteristics of the anthranilamide series. In a COLO 205 tumor pharmacodynamic assay measuring phosphorylation of the aurora-B substrate histone H3 at serine 10 (p-histone H3), oral administration of 8b at 50 mg/kg demonstrated significant reduction in tumor p-histone H3 for at least 6 h.


    Organizational Affiliation

    Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142 and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA. vcee@amgen.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
cDNA FLJ58295, highly similar to Serine/threonine-protein kinase 6
A, B
267Homo sapiensMutation(s): 0 
Gene Names: AURKA (AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6)
EC: 2.7.11.1
Find proteins for O14965 (Homo sapiens)
Go to Gene View: AURKA
Go to UniProtKB:  O14965
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
LJE
Query on LJE

Download SDF File 
Download CCD File 
A, B
N-{3-methyl-4-[(3-pyrimidin-4-ylpyridin-2-yl)oxy]phenyl}-3-(trifluoromethyl)benzamide
C24 H17 F3 N4 O2
OHDDQNLJTAKXQT-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.351 
  • R-Value Work: 0.285 
  • Space Group: C 2 2 21
Unit Cell:
Length (Å)Angle (°)
a = 118.320α = 90.00
b = 125.000β = 90.00
c = 76.110γ = 90.00
Software Package:
Software NamePurpose
CNSrefinement
SCALEPACKdata scaling
AMoREphasing
DENZOdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2010-07-27 
  • Released Date: 2010-08-18 
  • Deposition Author(s): Huang, X.

Revision History 

  • Version 1.0: 2010-08-18
    Type: Initial release
  • Version 1.1: 2011-07-13
    Type: Version format compliance